Targeting histone deacetylases: A novel therapeutic strategy for atrial fibrillation

Baigalmaa Lkhagva, Yu Hsun Kao, Yao Chang Chen, Tze Fan Chao, Shih Ann Chen, Yi Jen Chen

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Atrial fibrillation (AF) is a common cardiac arrhythmia associated with high mortality and morbidity. Current treatments of AF have limited efficacy and considerable side effects. Histone deacetylases (HDACs) play critical roles in the pathophysiology of cardiovascular diseases and contribute to the genesis of AF. Therefore, HDAC inhibition may prove a novel therapeutic strategy for AF through upstream therapy and modifications of AF electrical and structural remodeling. In this review, we provide an update of the knowledge of the effects of HDACs and HDAC inhibitors on AF, and dissect potential underlying mechanisms.

Original languageEnglish
JournalEuropean Journal of Pharmacology
DOIs
Publication statusPublished - 2016

Fingerprint

Histone Deacetylases
Atrial Fibrillation
Therapeutics
Atrial Remodeling
Cardiac Arrhythmias
Cardiovascular Diseases
Morbidity
Mortality

Keywords

  • Atrial fibrillation
  • HDAC inhibitors
  • Histone deacetylases
  • Non-histone proteins

ASJC Scopus subject areas

  • Pharmacology

Cite this

Targeting histone deacetylases : A novel therapeutic strategy for atrial fibrillation. / Lkhagva, Baigalmaa; Kao, Yu Hsun; Chen, Yao Chang; Chao, Tze Fan; Chen, Shih Ann; Chen, Yi Jen.

In: European Journal of Pharmacology, 2016.

Research output: Contribution to journalArticle

@article{08823e658da945eda51f394cfc48f7b2,
title = "Targeting histone deacetylases: A novel therapeutic strategy for atrial fibrillation",
abstract = "Atrial fibrillation (AF) is a common cardiac arrhythmia associated with high mortality and morbidity. Current treatments of AF have limited efficacy and considerable side effects. Histone deacetylases (HDACs) play critical roles in the pathophysiology of cardiovascular diseases and contribute to the genesis of AF. Therefore, HDAC inhibition may prove a novel therapeutic strategy for AF through upstream therapy and modifications of AF electrical and structural remodeling. In this review, we provide an update of the knowledge of the effects of HDACs and HDAC inhibitors on AF, and dissect potential underlying mechanisms.",
keywords = "Atrial fibrillation, HDAC inhibitors, Histone deacetylases, Non-histone proteins",
author = "Baigalmaa Lkhagva and Kao, {Yu Hsun} and Chen, {Yao Chang} and Chao, {Tze Fan} and Chen, {Shih Ann} and Chen, {Yi Jen}",
year = "2016",
doi = "10.1016/j.ejphar.2016.04.034",
language = "English",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",

}

TY - JOUR

T1 - Targeting histone deacetylases

T2 - A novel therapeutic strategy for atrial fibrillation

AU - Lkhagva, Baigalmaa

AU - Kao, Yu Hsun

AU - Chen, Yao Chang

AU - Chao, Tze Fan

AU - Chen, Shih Ann

AU - Chen, Yi Jen

PY - 2016

Y1 - 2016

N2 - Atrial fibrillation (AF) is a common cardiac arrhythmia associated with high mortality and morbidity. Current treatments of AF have limited efficacy and considerable side effects. Histone deacetylases (HDACs) play critical roles in the pathophysiology of cardiovascular diseases and contribute to the genesis of AF. Therefore, HDAC inhibition may prove a novel therapeutic strategy for AF through upstream therapy and modifications of AF electrical and structural remodeling. In this review, we provide an update of the knowledge of the effects of HDACs and HDAC inhibitors on AF, and dissect potential underlying mechanisms.

AB - Atrial fibrillation (AF) is a common cardiac arrhythmia associated with high mortality and morbidity. Current treatments of AF have limited efficacy and considerable side effects. Histone deacetylases (HDACs) play critical roles in the pathophysiology of cardiovascular diseases and contribute to the genesis of AF. Therefore, HDAC inhibition may prove a novel therapeutic strategy for AF through upstream therapy and modifications of AF electrical and structural remodeling. In this review, we provide an update of the knowledge of the effects of HDACs and HDAC inhibitors on AF, and dissect potential underlying mechanisms.

KW - Atrial fibrillation

KW - HDAC inhibitors

KW - Histone deacetylases

KW - Non-histone proteins

UR - http://www.scopus.com/inward/record.url?scp=84963979424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963979424&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2016.04.034

DO - 10.1016/j.ejphar.2016.04.034

M3 - Article

C2 - 27089819

AN - SCOPUS:84963979424

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

ER -